Climb Bio (CLYM) Total Current Liabilities (2020 - 2026)

Climb Bio (CLYM) has 7 years of Total Current Liabilities data on file, last reported at $4.1 million in Q1 2026.

• Quarterly Total Current Liabilities fell 42.14% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (down 42.14% YoY) and the FY2025 annual result came in at $7.0 million, up 41.63% from the prior year.
• Total Current Liabilities retreated to $4.1 million in Q1 2026, from $7.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $7.6 million in Q2 2022 to a low of $2.8 million in Q4 2023.
• A 5-year average of $5.0 million and a median of $4.9 million in 2024 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Current Liabilities tumbled 53.81% — and 2025, when it surged 138.51%.
• Tracing CLYM's Total Current Liabilities over 5 years: stood at $6.1 million in 2022, then tumbled by 53.53% to $2.8 million in 2023, then soared by 74.06% to $4.9 million in 2024, then jumped by 41.63% to $7.0 million in 2025, then slumped by 41.71% to $4.1 million in 2026.
• The last three Total Current Liabilities figures came in at $4.1 million (Q1 2026), $7.0 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.